Inclusion Criteria~1. Age between 50 and 80 years, inclusive.~2. Early Alzheimer's Disease (AD): a diagnosis of
Probable AD Dementia or Mild Cognitive Impairment (MCI) due to AD in accordance with the National Institute on
Aging-Alzheimer's Association (NIA-AA) Working Group Criteria \[Albert et al, 2011; McKhann et al, 2011\].~3.
One of the following apolipoprotein E (APOE) genotypes - either APOE4/4 (homozygous) or APOE3/4
(heterozygous).~4. MMSE score 22 to 30 inclusive; Clinical Dementia Rating (CDR)-Global Score of 0.5 or 1.0,
and CDR Memory Box Score of â‰¥ 0.5.~5. Documented confirmation of AD diagnosis by either positive amyloid
positron emission tomography (PET) or positive CSF AD signature. Subjects without documented positive AD
biomarker status must have a positive CSF biomarker result from a sample provided at screening.~6. Stable doses
of acetylcholinesterase for the duration of the study are allowed.~
